


Lamivudine salicylate

Cat. No.:	HY-B0250A
CAS No.:	173522-96-8
Molecular Formula:	C ₁₅ H ₁₇ N ₃ O ₆ S
Molecular Weight:	367.38
Target:	HIV; Reverse Transcriptase; HBV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Lamivudine (BCH-189) salicylate is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine salicylate can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS^{[1][2]}.

CUSTOMER VALIDATION

- Biomedicines. 2022, 10(2), 268.
- Int J Antimicrob Agents. 2019 Dec;54(6):814-819.
- J Cell Mol Med. 2021 Aug 10.
- Phytother Res. 2021 Jun 19.
- Molecules. 2022 May 18;27(10):3223.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Li, Y.C., [A clinical study on lamivudine treatment for advanced schistosomiasis with chronic B hepatitis]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi, 2013. 25(5): p. 548-9, 551.
- [2]. Zhang, C.E., et al., [Effects of lamivudine on growth of intestinal characteristic bacteria by microcalorimetry in vitro]. Yao Xue Xue Bao, 2013. 48(10): p. 1590-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA